Summary
For drugs with a high hepatic clearance, bioavailability is low due to the so-called “first pass effect”. Prediction of the bioavailability for these drugs has been only lossely tested. It is proposed that by plotting the reciprocal of bioavailability versus the oral clearance, a straight line with intercept of unity and slope of reciprocal of hepatic blood flow should ensue. For lignocaine and verapamil, this relationship was found to be strong and gave good predictability, whereas for propranolol this relationship was weak and gave poor predictability. The proposed method may be of value in determining whether the low bioavailability of a drug is due to hepatic first pass metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alván G, Borgå O, Lind M, Palmér L, Sieweres B (1977) First-pass hydroxylation of nortriptyline: Concentrations of parent drug and major metabolites in plasma. Eur J Clin Pharmacol 11: 219–224
De Boer AG, Breimer DD, Mattie H, Pronk J, Gubbens-Stibbe JM (1979) Rectal bioavailability of lidocaine in man: Partial avoidance of ‘first pass’ metabolism. Clin Pharmacol Ther 26: 701–709
Dutton GJ (1971) Glucuronide-forming enzymes. In: Brodie BB, Gillette JR (eds) Concepts in biochemical pharmacology, Part 2. Springer, Berlin Heidelberg New York, pp 373–400 (Handbook of experimental pharmacology, vol 28)
Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1981a) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotopelabelled verapamil. Eur J Clin Pharmacol 19: 133–137
Eichelbaum M, Dengler HJ, Somogyi A, von Unruh GE (1981b) Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets. Eur J Clin Pharmacol 19: 127–131
George CF (1979) Drug kinetics and hepatic blood flow. Clin Pharmacokinet 4: 433–440
Gibaldi M (1975) Comparison of observed and predicted bioavailability of nortriptyline in human following oral administration. J Pharm Sci 64: 1036–1037
Gibaldi M, Boyes RN, Feldman S (1971) Influence of first pass effect on availability of drugs on oral administration. J Pharm Sci 60: 1338–1340
Gilmore IT, Hofmann AF (1980) Altered drug metabolism and elevated serum bile acids in liver disease: A unified pharmacokinetic explanation. Gastroenterology 78: 176–178
Goldstein A (1964) Biostatistics: An introductory text. MacMillan, New York
Gomeni R, Bianchetti G, Sega R, Morselli PL (1977) Pharmacokinetics of propranolol in normal healthy volunteers. J Pharmacokinet Biopharm 5: 183–192
Gram LF, Christiansen J (1975) First-pass metabolism of imipramine in man. Clin Pharmacol Ther 17: 555–562
Harris PA, Riegelman S (1969) Influence of the route of administration on the area under the plasma concentration-time curve. J Pharm Sci 58: 71–75
Huet P-M, Lelorier J (1980) Effect of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. Clin Pharmacol Ther 28: 208–215
Kornhauser DM, Wood AJJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG (1978) Biological determinants of propranolol disposition in man. Clin Pharmacol Ther 23: 165–174
Perrier D, Gibaldi M (1972) Influence of first pass effect on the systemic availability of propoxyphene. J Clin Pharmacol 12: 449–452
Perrier D, Gibaldi M, Boyes RN (1973) Prediction of systemic availability from plasma level data after oral administration. J Pharm Pharmacol 25: 256–260
Perucca E, Richens A (1979) Reduction of oral bioavailability of lignocaine by induction of first-pass metabolism in epileptic patients. Br J Clin Pharmacol 8: 21–31
Routledge PA, Shand DG (1979) Clinical pharmacokinetics of propranolol. Clin Pharmacokinet 4: 73–90
Rowland M (1972) Influence of route of administration on drug availability. J Pharm Sci 61: 70–74
Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1: 123–135
Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10: 605–612
Somogyi A, Albrecht M, Kliems G, Schäfer R, Eichelbaum M (1981) Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 12: 51–60
Vestal RE, Kornhauser DM, Hollifield JW, Shand DG (1979) Inhibition of propranolol metabolism by chlorpromazine. Clin Pharmacol Ther 25: 19–24
Walle T, Fagan TC, Conradi EC, Walle UK, Gaffney TE (1979) Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther 26: 167–172
Wood AJJ, Carr K, Vestal RE, Belcher S, Wilkinson GR, Shand DG (1978) Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol 6: 345–350
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Somogyi, A., Eichelbaum, M. & Gugler, R. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol 22, 85–90 (1982). https://doi.org/10.1007/BF00606430
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606430